Stephen V Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Antonio Passaro discusses EGFR NSCLC at the International Lung Cancer Summit. Combination therapy should now be considered our standard for first-line therapy, with OS advantages seen using osi + chemo (FLAURA2) and amivantamab + lazertinib (MARIPOSA). Learning about impact on acquired resistance.”
More posts featuring Stephen V Liu.
